kwic
novel
novel
right
off
ON
99
1
100
500
strict
ELIZA cgi-bash version rev. 1.90
- Medical English LInking keywords finder for the PubMed Zipped Archive (ELIZA) -
return
kwic search for novel out of >500 occurrences
330250 occurrences (No.59 in the rank) during 5 years in the PubMed. [no cache] 500 found
--- ABSTRACT ---
--- ABSTRACT END ---
[frequency of next (right) word to novel]
330250 occurrences (No.59 in the rank) during 5 years in the PubMed. [no cache] 500 found
| 99) Clinical implications for the use of these therapies in NSCLC are discussed as they relate to their novel mechanisms of action, response patterns, and safety profiles. |
| PMID:24685885 DOI:10.1097/COC.0000000000000059 |
| 2015 American journal of clinical oncology |
| * Emerging immunotherapies in the treatment of non-small cell lung cancer (NSCLC): the role of immune checkpoint inhibitors. |
| - Immune checkpoint inhibition as a new treatment approach is undergoing extensive investigation in non-small cell lung cancer (NSCLC) and other malignancies. Unlike standard chemotherapy or targeted agents, which act directly on the tumor cells, immune checkpoint inhibitors work by restoring the immune system's capacity to eradicate tumors. Agents currently in active clinical development for lung cancer include ipilimumab, which modulates the cytotoxic T-lymphocyte-associated antigen 4 pathway, and multiple agents targeting the programmed death protein 1 (PD-1) pathway, both anti-PD-1 compounds (nivolumab, pembrolizumab [MK-3475]) and those that target programmed death ligand 1 (PD-L1), a key ligand for PD-1 (BMS-936559, MPDL3280A). Preliminary evidence shows activity for these agents in NSCLC as monotherapy or in combination with chemotherapy. This article reviews the immune checkpoint inhibitors and the available data to date on their use in lung cancer. Clinical implications for the use of these therapies in NSCLC are discussed as they relate to their novel mechanisms of action, response patterns, and safety profiles. |
[
right
kwic]
(1)22  therapeutic |
(17)3 mutation |
(33)2 approaches |
(49)2 information |
| (2)11 and |
(18)3 paradigm |
(34)2 autosomal |
(50)2 inhibitors |
| (3)8 mechanism |
(19)3 role |
(35)2 candidate |
(51)2 learning |
| (4)8 method |
(20)3 strain |
(36)2 cardiac |
(52)2 modulators |
| (5)7 approach |
(21)3 target |
(37)2 clinical |
(53)2 object |
| (6)7 mutations |
(22)3 targeted |
(38)2 compounds |
(54)2 oral |
| (7)6 therapies |
(23)3 targets |
(39)2 data |
(55)2 polymer |
| (8)5 technique |
(24)3 treatment |
(40)2 described |
(56)2 potent |
| (9)4 strategies |
(25)3 type |
(41)2 dual |
(57)2 prognostic |
| (10)4 strategy |
(26)3 words |
(42)2 electroporation |
(58)2 putative |
| (11)4 surgical |
(27)2 *null* | (43)2 finding |
(59)2 recombinants |
| (12)3 antibacterial |
(28)2 anti-tumor |
(44)2 findings |
(60)2 results |
| (13)3 drug |
(29)2 antibiotic |
(45)2 form |
(61)2 therapeutical |
| (14)3 homozygous |
(30)2 anticancer |
(46)2 genetic |
(62)2 titanium |
| (15)3 insights |
(31)2 application |
(47)2 imaging |
(63)2 treatments |
| (16)3 mechanisms |
(32)2 applications |
(48)2 in |
add keyword
--- WordNet output for novel ---